

California Statistics

PCSK9 Inhibitors



About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in California from January 2017 through December 2017.

Key California Findings



Rejection Rate:

24%



Appeals Rate:

35%



Final Rejections:

6,372

Of health plans that received at least 400 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- BS of CA **60%**
- Centene **46%**
- Express Scripts **48%**
- Anthem **40%**

The following had **the lowest rates of rejection:**

- Aetna **14%**
- Humana Health Plan **9%**



The following table details claims data for the California managed care organizations that received at least 400 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
BS Of CA	60%	1,121	668
Express Scripts	48%	1,164	554
Centene	46%	469	218
Anthem	40%	1,278	510
United Health Group	22%	5,204	1,154
California Public Employees Retirement System Calpers	18%	1,170	215
Rite Aid	18%	444	79
Cigna Healthcare	17%	568	98
CVS Health	16%	3,511	556
Wellcare Management Group	15%	475	73
Aetna	14%	2,206	314
Humana Health Plan	9%	3,851	354

Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

